Cartesian Therapeutics, Inc.
RNACNASDAQHealthcare● Active
$5.86
+$0.02(+0.34%)
Market Cap$172175590
P/E Ratio—
52W High$15.57
52W Low$5.6
Cartesian Therapeutics, Inc. (RNAC) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RNAC · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 30, 2026EPS Actual
-$1.46
Est. -$0.84 · -73.8%
Revenue
$0.00B
Est. $0.00B · -64.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 30, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
RNAC reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.87 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | Apr 30, 2026 | -$0.84 | -$1.46 | -73.8% | $0.00B | $0.00B | -64.5% |
| ▼ Q1 FY2026 | Mar 9, 2026 | -$0.82 | -$1.38 | -68.3% | $0.00B | $0.00B | +529.9% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.81 | -$1.38 | -70.4% | $0.00B | $0.00B | +351.0% |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.76 | $0.50 | +165.8% | $0.00B | $0.00B | +67.8% |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.61 | -$0.68 | -11.5% | $0.00B | $0.00B | +60.0% |
| ▲ Q1 FY2025 | Mar 20, 2025 | -$0.78 | -$0.59 | +24.4% | $0.00B | $0.00B | -24.1% |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.78 | -$0.69 | +11.5% | $0.00B | $0.00B | +238.6% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.87
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 30, 2026Miss
EPS Actual
-$1.46
EPS Est.
-$0.84
EPS Surpr.
-73.8%
Revenue
$0.00B
Q1 FY2026
Mar 9, 2026Miss
EPS Actual
-$1.38
EPS Est.
-$0.82
EPS Surpr.
-68.3%
Revenue
$0.00B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$1.38
EPS Est.
-$0.81
EPS Surpr.
-70.4%
Revenue
$0.00B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
$0.50
EPS Est.
-$0.76
EPS Surpr.
+165.8%
Revenue
$0.00B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.68
EPS Est.
-$0.61
EPS Surpr.
-11.5%
Revenue
$0.00B
Q1 FY2025
Mar 20, 2025Beat
EPS Actual
-$0.59
EPS Est.
-$0.78
EPS Surpr.
+24.4%
Revenue
$0.00B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.69
EPS Est.
-$0.78
EPS Surpr.
+11.5%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2030 | $-0.74 | $-0.46 | $-0.14 | 1 |
| Q3 FY2030 | $-0.92 | $-0.57 | $-0.18 | 1 |
| Q2 FY2030 | $-1.07 | $-0.66 | $-0.21 | 1 |
| Q1 FY2030 | $-1.19 | $-0.74 | $-0.23 | 1 |
| Q4 FY2029 | $-1.25 | $-0.77 | $-0.24 | 1 |
| Q3 FY2029 | $-1.23 | $-0.76 | $-0.24 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2030 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2030 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2030 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2030 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2029 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2029 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Apr 30, 2026 | -73.8% | $6.47 | $6.22 | -3.86% |
| ▼ Q1 FY2026 | Mar 9, 2026 | -68.3% | $6.85 | $9.02 | +31.68% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -70.4% | $7.67 | $7.55 | -1.56% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +165.8% | $11.28 | $10.54 | -6.56% |
| ▼ Q2 FY2025 | May 8, 2025 | -11.5% | $10.15 | $10.42 | +2.66% |
| ▲ Q1 FY2025 | Mar 20, 2025 | +24.4% | $15.46 | $15.93 | +3.04% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +11.5% | $20.86 | $20.78 | -0.38% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +150.5% | $14.21 | $12.87 | -9.43% |
Q2 FY2026-3.86%
Report Date
Apr 30, 2026
EPS Beat/Miss
-73.8%
Price Before
$6.47
Price After
$6.22
Q1 FY2026+31.68%
Report Date
Mar 9, 2026
EPS Beat/Miss
-68.3%
Price Before
$6.85
Price After
$9.02
Q4 FY2025-1.56%
Report Date
Nov 6, 2025
EPS Beat/Miss
-70.4%
Price Before
$7.67
Price After
$7.55
Q3 FY2025-6.56%
Report Date
Aug 7, 2025
EPS Beat/Miss
+165.8%
Price Before
$11.28
Price After
$10.54
Q2 FY2025+2.66%
Report Date
May 8, 2025
EPS Beat/Miss
-11.5%
Price Before
$10.15
Price After
$10.42
Q1 FY2025+3.04%
Report Date
Mar 20, 2025
EPS Beat/Miss
+24.4%
Price Before
$15.46
Price After
$15.93
Q4 FY2024-0.38%
Report Date
Nov 7, 2024
EPS Beat/Miss
+11.5%
Price Before
$20.86
Price After
$20.78
Q3 FY2024-9.43%
Report Date
Aug 8, 2024
EPS Beat/Miss
+150.5%
Price Before
$14.21
Price After
$12.87
Avg Beat Reaction-3.33%
Avg Miss Reaction+7.23%
Beat Rate4 / 8 quarters
Largest Move+31.68% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RNAC ends December
Cartesian Therapeutics, Inc. (RNAC) most recently reported earnings on April 30, 2026 for Q2 FY2026, posting EPS of $-1.46 — missing the analyst consensus of $-0.84 by -73.8%. The next RNAC earnings date is expected around September 1, 2026.
Each quarter, investors track RNAC earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RNAC revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RNAC's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RNAC earnings · 5 questionsCartesian Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. RNAC typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RNAC historically reports after market close (AMC).
RNAC earnings datewhen is RNAC earningsRNAC next earnings datewhen does RNAC report earningsRNAC earnings calendar
▸ Source: FMP · Cartesian Therapeutics, Inc. SEC filings · US GAAP · Cartesian Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026